Spyre Therapeutics Inc. (SYRE) — Cash Flow-to-Debt Ratio
Spyre Therapeutics Inc. (SYRE) has a Cash Flow-to-Debt Ratio of -0.62x as of March 2026, meaning its operating cash flow of $-57.54 Million could theoretically repay -1% of its total liabilities ($93.14 Million) in one year. See cash generation quality of Spyre Therapeutics Inc. to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Spyre Therapeutics Inc. Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Spyre Therapeutics Inc. across 12 annual periods. Also explore Spyre Therapeutics Inc. (SYRE) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Spyre Therapeutics Inc. (2014–2025)
Year-by-year debt coverage analysis for Spyre Therapeutics Inc.. For market capitalisation and broader financial context, see Spyre Therapeutics Inc. market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.71x | $-169.25 Million | $62.55 Million | ▼ -55.9% |
| 2024 | -1.74x | $-157.41 Million | $90.68 Million | ▼ -174.2% |
| 2023 | -0.63x | $-99.91 Million | $157.84 Million | ▲ +83.5% |
| 2022 | -3.85x | $-80.14 Million | $20.84 Million | ▼ -86.0% |
| 2021 | -2.07x | $-53.72 Million | $25.98 Million | ▲ +40.6% |
| 2020 | -3.48x | $-75.78 Million | $21.79 Million | ▼ -22.3% |
| 2019 | -2.84x | $-65.69 Million | $23.10 Million | ▲ +8.9% |
| 2018 | -3.12x | $-32.19 Million | $10.31 Million | ▲ +27.2% |
| 2017 | -4.29x | $-24.61 Million | $5.74 Million | ▲ +6.7% |
| 2016 | -4.60x | $-18.84 Million | $4.10 Million | ▼ -6.8% |
| 2015 | -4.31x | $-10.98 Million | $2.55 Million | ▲ +37.9% |
| 2014 | -6.93x | $-7.33 Million | $1.06 Million | — |